[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0812005A2 - humanized antibodies to ab (20-42) globulomers and their uses. - Google Patents

humanized antibodies to ab (20-42) globulomers and their uses.

Info

Publication number
BRPI0812005A2
BRPI0812005A2 BRPI0812005A BRPI0812005A BRPI0812005A2 BR PI0812005 A2 BRPI0812005 A2 BR PI0812005A2 BR PI0812005 A BRPI0812005 A BR PI0812005A BR PI0812005 A BRPI0812005 A BR PI0812005A BR PI0812005 A2 BRPI0812005 A2 BR PI0812005A2
Authority
BR
Brazil
Prior art keywords
globulomers
humanized antibodies
humanized
antibodies
Prior art date
Application number
BRPI0812005A
Other languages
Portuguese (pt)
Inventor
R Striebinger Andreas
Labkovsky Boris
R Hinton Paul
Barghorn Stefan
Ebert Ulrich
M Juan Veronica
Original Assignee
Abbott Gmbh & Co Kg
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39791050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0812005(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg, Abbott Lab filed Critical Abbott Gmbh & Co Kg
Publication of BRPI0812005A2 publication Critical patent/BRPI0812005A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0812005A 2007-05-30 2008-05-30 humanized antibodies to ab (20-42) globulomers and their uses. BRPI0812005A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94093207P 2007-05-30 2007-05-30
US99035907P 2007-11-27 2007-11-27
PCT/US2008/065205 WO2008150949A1 (en) 2007-05-30 2008-05-30 HUMANIZED ANTIBODIES TO Aß(20-42) GLOBULOMER AND USES THEREOF

Publications (1)

Publication Number Publication Date
BRPI0812005A2 true BRPI0812005A2 (en) 2019-09-24

Family

ID=39791050

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812005A BRPI0812005A2 (en) 2007-05-30 2008-05-30 humanized antibodies to ab (20-42) globulomers and their uses.

Country Status (22)

Country Link
US (1) US20090175847A1 (en)
EP (1) EP2150563A1 (en)
JP (1) JP2010530740A (en)
KR (1) KR20100032398A (en)
CN (1) CN101827862A (en)
AR (1) AR066794A1 (en)
AU (1) AU2008260062A1 (en)
BR (1) BRPI0812005A2 (en)
CA (1) CA2687414A1 (en)
CL (1) CL2008001580A1 (en)
CO (1) CO6251291A2 (en)
CR (1) CR11179A (en)
DO (1) DOP2009000269A (en)
EC (1) ECSP099833A (en)
IL (1) IL202243A0 (en)
MX (1) MX2009012950A (en)
PA (1) PA8782201A1 (en)
PE (1) PE20090329A1 (en)
RU (1) RU2009149370A (en)
TW (1) TW200914465A (en)
UY (1) UY31114A1 (en)
WO (1) WO2008150949A1 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
ES2432112T3 (en) * 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibition of factor B, of the alternative complement pathway and related methods
US20060270922A1 (en) 2004-07-13 2006-11-30 Brauker James H Analyte sensor
US7713574B2 (en) 2004-07-13 2010-05-11 Dexcom, Inc. Transcutaneous analyte sensor
PT3540062T (en) * 2004-11-16 2021-07-06 Humanigen Inc Immunoglobulin variable region cassette exchange
JP5707024B2 (en) * 2005-05-26 2015-04-22 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ Agents that inhibit the complement alternative pathway to treat traumatic brain injury, spinal cord injury and related conditions
EP2289909B1 (en) 2005-11-30 2014-10-29 AbbVie Inc. Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
KR101434935B1 (en) 2005-11-30 2014-10-01 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
KR101505201B1 (en) 2005-12-12 2015-03-24 에이씨 이뮨 에스.에이. A beta 1-42 specific monoclonal antibodies with therapeutic properties
EP2046833B9 (en) * 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US7964705B2 (en) * 2007-03-14 2011-06-21 Taligen Therapeutics, Inc. Humaneered anti-factor B antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CA2701793C (en) 2007-10-05 2017-04-25 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
CN101998863B (en) * 2007-10-05 2015-09-16 基因技术公司 The purposes of anti-amyloid beta antibody in oculopathy
US8323651B2 (en) 2008-05-09 2012-12-04 Abbott Laboratories Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AU2013202020B2 (en) * 2009-07-31 2014-11-27 F. Hoffmann-La Roche Ag Subcutaneous anti-HER2 antibody formulation
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
AR080446A1 (en) 2010-03-03 2012-04-11 Boehringer Ingelheim Int UNION TO A-BETA POLYPEPTIDES (AMYLOID BETA)
KR20130010123A (en) * 2010-04-07 2013-01-25 아비에 인코포레이티드 TNF-α BINDING PROTEINS
WO2011130377A2 (en) * 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
MX341369B (en) 2010-07-30 2016-08-17 Genentech Inc * Safe and functional humanized anti beta-amyloid antibody.
CN105348387B (en) * 2010-08-14 2020-08-25 Abbvie 公司 Amyloid beta binding proteins
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
CN102516360B (en) * 2011-12-08 2013-11-06 清华大学 Polypeptide capable of inhibiting beta-secretase digestion effect and application thereof
EP2855529A4 (en) 2012-05-24 2015-12-09 Alexion Pharma Inc Humaneered anti-factor b antibody
PE20150646A1 (en) 2012-08-16 2015-05-21 Ipierian Inc METHODS OF TREATING A TAUOPATHY
KR102450670B1 (en) 2012-10-15 2022-10-04 메디뮨 리미티드 Antibodies to amyloid beta
NZ630610A (en) * 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
TWI806150B (en) 2014-11-07 2023-06-21 瑞士商諾華公司 Stable protein solution formulation containing high concentration of an anti-vegf antibody
PT3827845T (en) 2015-11-03 2022-07-08 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
EP3999532A2 (en) * 2019-07-16 2022-05-25 Sanofi Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease
CN117589996A (en) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 Diagnostic use of highly toxic amyloid oligomers
CN117491650B (en) * 2023-11-01 2024-09-20 首都医科大学宣武医院 Quantitative detection kit, detection method and application of peripheral blood Hb-Abeta complex

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529938A (en) * 1983-02-14 1985-07-16 Shell Oil Company High frequency induction method for locating the interface between formations having the same resistivity
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US6492107B1 (en) * 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3590766T (en) * 1985-03-30 1987-04-23
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988007089A1 (en) * 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4880078A (en) * 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) * 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991006287A1 (en) * 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
US5780225A (en) * 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0463151T3 (en) * 1990-01-12 1996-07-01 Cell Genesys Inc Generation of xenogenic antibodies
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0542810A1 (en) * 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5698426A (en) * 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1992018619A1 (en) * 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
ES2181673T3 (en) * 1991-05-01 2003-03-01 Jackson H M Found Military Med PROCESS OF TREATMENT OF INFECTIOUS RESPIRATORY DISEASES.
CA2103887C (en) * 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5912120A (en) * 1992-04-09 1999-06-15 The United States Of America As Represented By The Department Of Health And Human Services, Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism
US5934272A (en) * 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5565352A (en) * 1993-11-24 1996-10-15 Arch Development Corporation Deubiquitinating enzyme: compositions and methods
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6091001A (en) * 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) * 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
JPH11503914A (en) * 1995-04-21 1999-04-06 セル ジェネシス，インコーポレイテッド Generation of large genomic DNA deletions
CA2230494A1 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
JP2978435B2 (en) * 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
ATE508733T1 (en) * 1996-03-04 2011-05-15 Penn State Res Found MATERIALS AND METHODS FOR INCREASE CELLULAR INTERNALIZATION
US5714352A (en) * 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6699658B1 (en) * 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5916771A (en) * 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2330330T3 (en) * 2000-06-28 2009-12-09 Glycofi, Inc. PROCEDURE OF PRODUCTION OF MODIFIED GLUCOPROTEINS.
US7449308B2 (en) * 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US20030186374A1 (en) * 2001-10-01 2003-10-02 Hufton Simon E. Multi-chain eukaryotic display vectors and uses thereof
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JP2007528723A (en) * 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド Antibody humanization
SE0401601D0 (en) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
BRPI0610093A2 (en) * 2005-05-05 2008-12-09 Merck & Co Inc pharmaceutical composition, and method for preventing or treating a disease associated with alpha-beta amyloid deposits in a patient's brain

Also Published As

Publication number Publication date
CL2008001580A1 (en) 2008-12-05
WO2008150949A1 (en) 2008-12-11
AR066794A1 (en) 2009-09-09
PA8782201A1 (en) 2009-02-09
UY31114A1 (en) 2009-01-05
CR11179A (en) 2010-05-27
EP2150563A1 (en) 2010-02-10
JP2010530740A (en) 2010-09-16
KR20100032398A (en) 2010-03-25
DOP2009000269A (en) 2009-12-15
TW200914465A (en) 2009-04-01
PE20090329A1 (en) 2009-03-27
CO6251291A2 (en) 2011-02-21
MX2009012950A (en) 2010-03-26
US20090175847A1 (en) 2009-07-09
CA2687414A1 (en) 2008-12-11
ECSP099833A (en) 2010-01-29
RU2009149370A (en) 2011-07-10
IL202243A0 (en) 2010-06-16
CN101827862A (en) 2010-09-08
AU2008260062A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
BRPI0812005A2 (en) humanized antibodies to ab (20-42) globulomers and their uses.
CY2021027I2 (en) ANTI-CD20 ANTIBODY PREPARATION
CY2019004I1 (en) MODIFIED ANTI-IL-23P19 ANTIBODIES
BRPI0815983A2 (en) humanized anti-cxcr5 antibodies derived from them and their uses
BRPI0813985A2 (en) human antibodies to human cd20 and method for their use.
BRPI0718182A2 (en) OLIGORRIBONUCLEOTIDS AND THEIR USES.
BRPI1012321A2 (en) anti-vegf antibodies and their uses
BRPI0821405A2 (en) Bispecific, bivalent antibodies
BRPI0821375A2 (en) Bispecific, bivalent antibodies
BRPI1008692A2 (en) antibody molecules having human ox40 specificity.
BRPI1009420A2 (en) axmi-001, axmi-002, axmi-030, and axmi-045; toxin genes and methods for their use
NO344963B1 (en) Humanized antibody
DK2234600T3 (en) ANTIBODY FORMULATION
DK2061814T3 (en) Antibodies and immunoconjugates and their use.
DK2152748T3 (en) Anti-Notch1 NRR antibodies and methods for their use
BRPI0821777A2 (en) Bivalent bispecific antibodies
BRPI0817881A2 (en) Organic compounds and their uses
BRPI0816785A2 (en) rationally designed synthetic antibody libraries, and uses thereof
BRPI1010540A2 (en) "antibodies specific for dkk-1 and their uses"
BRPI0808098A2 (en) 4-ARYL-1,4-DI-HYDRO-1,6-NAPHTHRIDINAMIDS REPLACED AND THEIR USE
BRPI0814252A2 (en) Antibody Formulations
BRPI1016150A2 (en) heterocyclic compounds and their uses.
BRPI0807991A2 (en) PREPARED ANTI-IL-23R ANTIBODIES.
BRPI0906498A2 (en) Ron antibody and its uses
BRPI0917370A2 (en) engineered anti-yl-13 antibodies, compositions, methods and uses.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.